Alexander Drilon, MD, on NTRK Fusion Basics: An Expert Overview

Posted: Sunday, August 1, 2021

Alexander E. Drilon, MD, of Memorial Sloan Kettering Cancer Center, reviews the current landscape of NTRK fusions, drivers of multiple cancers in children and adults, and the effective first-generation targeted therapies (larotrectinib and entrectinib) approved by the U. S. Food and Drug Administration to treat them.